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Breast cancer is the most commonly diagnosed 
cancer and the second leading cause of cancer 
death in women. Survival of breast cancer patients 
has steadily improved because of early screen­
ing and adjuvant therapy. Distressingly, how­
ever, for women with metastatic disease there 
has been little change in overall survival over 
the last 30 yr (Jemal et al., 2010), and it con­
sequently accounts for over 90% deaths from 
breast cancer (Joyce and Pollard, 2009; Sleeman 
and Steeg, 2010). This indicates that metastatic 
breast cancer is largely refractory to current thera­
peutic strategies. Tumor cell seeding and meta­
static growth are the two major rate­limiting 
steps for distal metastasis (Fidler, 2003). Al­
though mutations in tumor cells account for their 
acquisition of malignancy, several mechanisms 
involved in tumor cell extravasation and meta­
static seeding are mediated through nontumor­ 
derived microenvironmental factors (Qian et al., 
2011; Gil­Bernabé et al., 2012; Labelle and 
Hynes, 2012; Peinado et al., 2012; Quail and 
Joyce, 2013).
In the tumor microenvironment, there is 
compelling evidence that macrophages that 
infiltrate most cancers promote tumor progres­
sion to malignancy and enhance metastasis 
(Mantovani and Sica, 2010; Qian and Pollard, 
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Although the link between inflammation and cancer initiation is well established, its role  
in metastatic diseases, the primary cause of cancer deaths, has been poorly explored. Our 
previous studies identified a population of metastasis-associated macrophages (MAMs) 
recruited to the lung that promote tumor cell seeding and growth. Here we show that 
FMS-like tyrosine kinase 1 (Flt1, also known as VEGFR1) labels a subset of macrophages in 
human breast cancers that are significantly enriched in metastatic sites. In mouse models 
of breast cancer pulmonary metastasis, MAMs uniquely express FLT1. Using several genetic 
models, we show that macrophage FLT1 signaling is critical for metastasis. FLT1 inhibition 
does not affect MAM recruitment to metastatic lesions but regulates a set of inflammatory 
response genes, including colony-stimulating factor 1 (CSF1), a central regulator of macro-
phage biology. Using a gain-of-function approach, we show that CSF1-mediated autocrine 
signaling in MAMs is downstream of FLT1 and can restore the tumor-promoting activity  
of FLT1-inhibited MAMs. Thus, CSF1 is epistatic to FLT1, establishing a link between FLT1 
and inflammatory responses within breast tumor metastases. Importantly, FLT1 inhibition 
reduces tumor metastatic efficiency even after initial seeding, suggesting that these path-
ways represent therapeutic targets in metastatic disease.
© 2015 Qian et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/ 
by-nc-sa/3.0/).
T
h
e 
Jo
u
rn
al
 o
f 
E
xp
er
im
en
ta
l 
M
ed
ic
in
e
 o
n
 Septem
ber 9, 2015
jem.rupress.org
D
ow
nloaded from
 
Published August 10, 2015
http://jem.rupress.org/content/suppl/2015/08/06/jem.20141555.DC1.html 
Supplemental Material can be found at:
 o
n
 Septem
ber 9, 2015
jem.rupress.org
D
ow
nloaded from
 
 o
n
 Septem
ber 9, 2015
jem.rupress.org
D
ow
nloaded from
 
1434 Macrophage FLT1 mediates breast cancer metastasis | Qian et al.
RESULTS
Host FLT1 signaling is critical for breast cancer metastasis
Flt1tk is a targeted mutation that deletes the tyrosine kinase 
domain of FLT1 while retaining both the cell surface and se­
creted form of the receptor. Thus, this mutation ablates FLT1 
intracellular signaling capacity but retains its VEGF neutral­
ization capacity, a function that is critical during embryo 
development (Hiratsuka et al., 1998). To define the role of 
FLT1 signaling in metastasis, we crossed Flt1tk mice with the 
widely used polyoma middle T (MMTV­PyMT) mouse model 
for human luminal breast cancers. These mice, whose tumors 
are caused by the mammary epithelial restricted expression of 
the PyMT oncogene, recapitulate disease progression in pa­
tients with luminal breast cancers and metastasize to lung with 
high penetrance (Hutchinson and Muller, 2000; Lin et al., 
2003). Ablation of FLT1 signaling in the Flt1tk/tk homozygous 
mice does not have a significant effect on PyMT primary 
tumor burden at 19 wk of age compared with heterozygous 
littermates (Fig. 1 a). However, metastatic burden (Mets index, 
defined by percentage of tumor volume in total lung volume 
using stereological quantification [Qian et al., 2009]) is sig­
nificantly reduced in the Flt1tk/tk­null mutants compared with 
their heterozygous littermates (Fig. 1, b and c). Both macro­
phages and endothelial cells express FLT1 in vivo. Previous 
studies indicated that macrophage–tumor cell paracrine sig­
naling promotes tumor cell migration, which leads to in­
creased tumor cell intravasation and distal metastasis (Condeelis 
and Pollard, 2006). To test whether FLT1 signaling is involved 
in promoting tumor cell escape from the primary tumor, we 
measured the number of circulating tumor cells and found 
no difference between FLT1tk/tk mice and Flt1tk/+ littermate 
control (Fig. 1 d). To further test whether macrophage FLT1 
signaling is involved in promoting tumor cell migration, we 
used an in vitro split Boyden chamber assay that measures this 
effect and did not detect a difference between Flt1tk/tk and 
Flt1tk/+ littermate control bone marrow–derived primary mac­
rophages (BMMs; Fig. 1 e). Together, these data indicate that 
FLT1 signaling is critical for spontaneous metastasis but does 
not affect tumor migration and intravasation in the primary 
tumor in this model of breast cancer.
Previous studies suggested that FLT1 is a decoy receptor 
without intrinsic tyrosine kinase activity in endothelial cells 
attenuating VEGF activity, but it is an active tyrosine kinase 
receptor in macrophages (Shibuya, 2006). To exclude the in­
volvement of endothelial FLT1 in metastasis, we generated 
bone marrow mosaic mice using Flt1tk/tk mice or Flt1tk/+ lit­
termates as bone marrow donor in lethally irradiated C57BL/6 
mice to restrict the targeted mutation to bone marrow– 
derived hematopoietic cells (Fig. 1 f). To further confirm our 
findings, we used another murine breast cancer model in 
C57BL/6 background, E0771­LG, to perform spontaneous 
metastasis assay with orthotopic injection, followed by tumor 
resection when they reach 1 cm in diameter 4 wk later in 
these bone marrow mosaic mice (Fig. 1 f). This hematopoietic­
specific genetic loss of function of FLT1 signaling significantly 
inhibited total pulmonary metastasis burden of E0771­LG 
2010; Ruffell et al., 2012). At the metastatic site, metastasis­ 
associated macrophages (MAMs) have been shown to stimulate 
tumor cell extravasation, survival, and subsequent growth in 
preclinical breast cancer lung metastasis models (Qian et al., 
2009, 2011; Chen et al., 2011). Specifically, MAM­derived 
vascular endothelial growth factor (VEGF) can promote tumor 
cell extravasation at the metastatic site in part by increased 
vascular permeability (Qian et al., 2011). As patients usually 
present with established metastasis, these data argue that tar­
geting the macrophage functions in the metastatic sites could 
have therapeutic potential (De Palma and Lewis, 2013). How­
ever, the mechanisms by which MAMs promote metastatic 
growth after seeding are still largely unknown.
Detailed immune­phenotyping of cell surface markers in­
dicated that MAMs express a high level of surface FMS­like 
tyrosine kinase 1 (FLT1) compared with lung­resident mac­
rophages and splenic macrophages (Qian et al., 2009). FLT1 
is a family member of VEGF receptor (VEGFR) transmem­
brane receptor tyrosine kinases that binds to VEGF and pla­
cental growth factor (PlGF; Olsson et al., 2006). VEGF plays 
an important role in tumor progression through its regulation 
of angiogenesis. However, these effects are largely mediated 
by VEGFR2 expressed by endothelial cells, and as a conse­
quence of this activity, VEGF and VEGFR2 have been tar­
geted for cancer therapy. In contrast, FLT1 is considered to 
have minimal signaling activity and largely to be a decoy re­
ceptor that titrates VEGF activity (Shibuya, 2006), although 
in macrophages there is evidence that FLT1 acts as a chemo­
tactic receptor (Murakami et al., 2008; Beck et al., 2010). 
However, the role of macrophage FLT1 in breast cancer me­
tastasis has not been determined.
In the current study, we show in human breast cancer 
that FLT1 labels a subset of tumor­associated macrophages 
(TAMs) and FLT1+ stroma are significantly enriched in breast 
cancer metastasis samples compared with primary tumors. 
Combining genetic models of macrophage­specific Flt1 defi­
ciency and FLT1 inhibitory antibody, we show that FLT1 
signaling in MAMs is important for tumor cell survival after 
metastatic seeding, which suggests that targeting these path­
ways will have therapeutic efficacy in metastatic disease. 
Rather than mediating macrophage recruitment, we show a 
novel activity of FLT1 signaling in regulating a set of inflam­
matory response genes in the MAMs in vivo. These genes 
include colony-stimulating factor 1 (Csf1), a major regulator of 
the mononuclear phagocytic lineage (Chitu and Stanley, 2006) 
that is up­regulated in breast cancer patients with poor prognosis 
and metastatic disease (Scholl et al., 1994, 1996; McDermott 
et al., 2002). Importantly, we show local CSF1 overexpression 
reverts the inhibitory effect of FLT1 inhibition on tumor cell 
distal seeding efficiency. Mechanistically, FAK1 acts down­
stream of FLT1 signaling and regulates CSF1 expression. Thus, 
our data illustrated a novel mechanism of CSF1­mediated 
autocrine signaling downstream of FLT1 in macrophages 
that directly links the inflammatory response with VEGF 
action and that is critical for the metastasis­promoting func­
tion of MAMs.
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site. To examine specifically the effect of FLT1 signaling on 
events at the distal metastatic site (seeding and persistent growth) 
we performed experimental metastasis (lung colonization) as­
says using the PyMT tumor–derived metastatic Met­1 cell line 
(Borowsky et al., 2005) in Flt1tk/tk mice crossed with Rag2/ 
immune­deficient mice. Deficiency in FLT1 signaling in 
homozygous Flt1tk/tk mice significantly reduced the metastatic 
cells when harvested at 8 wk (Fig. 1, g and h) and significantly 
prolonged the survival (Fig. 1 i) of these mice compared with 
their WT controls. These data further confirmed that breast 
cancer distal metastasis was dependent on host hematopoietic 
FLT1 signaling.
In spontaneous models, metastasis is the result of distinct 
metastatic events at the primary tumor and those at the metastatic 
Figure 1. Stromal FLT1 is important for breast cancer pulmonary metastasis. (a) Total tumor burden of PyMT; Flt1tk/+ or PyMT; Flt1tk/tk mice at  
19 wk of age. (b) Representative H&E-stained section of lung metastasis nodules of PyMT; Flt1tk/+ (top) or PyMT; Flt1tk/tk mice (bottom; arrowheads).  
(c) Stereological quantification of lung metastasis index at 19 wk of age. Mets index is equal to total metastasis volume normalized by total lung volume. 
Bars show median with interquartile range; n ≥ 12; ***, P < 0.001 by Mann-Whitney test. (d) Quantification of circulating tumor cell number by relative 
PyMT gene expression in CD45-circulating cells in age-matched littermate mice bearing late stage tumors. Bars represent median ± interquartile range;  
n = 12; not significant by Mann-Whitney test. (e) BMMs induce Met-1 cell invasion in a modified transwell invasion assay, whereas Flt1tk/tk macrophages 
show no difference compared with WT macrophages. Error bars indicate SEM. n = 3 with duplicate; *, P < 0.05; not significant between WT and Flt1tk/tk 
BMM by one-way ANOVA with Tukey’s multiple comparison. (f) Spontaneous metastasis of E0771 cells in littermate heterozygous or homozygous for 
Flt1tk targeted mutation. (g) Representative automatically stitched scanned images of H&E-stained lung cross section. (b and g) Bars, 1 mm. (h) Stereo-
logical quantification of mice harvested at 8 wk. Metastasis quantification was the same as in c. Mean + SEM; n = 9; *, P < 0.05 by Mann-Whitney test.  
(i) Survival curve of mice left to monitor. Death is defined as time the mice became moribund; n ≥ 13; P = 0.022 by log-rank test. (j–l) Stereological quan-
tification of the distal metastasis efficiency of Met-1 cells in mice heterozygous or homozygous for Flt1tk targeted mutation. Mets index (j) was the same as  
in c; metastasis number index (k) is equal to averaged number of metastasis sites per square millimeter lung area; average diameter (l) is the averaged size 
of metastasis nodules in millimeters. Bars represent mean ± SEM. n ≥ 8; **, P < 0.01; ***, P < 0.001 by Student’s t test.
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from a triple­negative patient (Minn et al., 2005; Neve et al., 
2006), and tested their dependence for metastasis on host FLT1 
tyrosine kinase activity in immune­deficient Rag2/; Flt1tk/+ 
and Rag2/; Flt1tk/tk mice (Fig. 2 a). The lung metastatic 
tumor burden of 4173 cells is significantly reduced in Flt1tk/tk 
mice compared with littermate Flt1tk/+ mice (Fig. 2 b). This 
reduction in metastatic burden was the result of both a reduced 
number and the size of metastatic nodules (Fig. 2, c and d).
To further exclude the involvement of endothelial FLT1 
in human breast cancer metastasis, we used a bone marrow 
transplant approach to generate mosaic mice using Rag2/; 
Flt1tk/tk mice or Rag2/; Flt1tk/+ littermates as bone mar­
row donor in lethally irradiated nude mice (Fig. 2 e). This 
hematopoietic­specific blockade of FLT1 signaling significantly 
inhibited the total metastasis burden of 4173 cells compared 
with control mice (Fig. 2 f). Similar to the data observed with 
the total body Flt1tk/tk mutants, this inhibition also resulted in 
reduction in both the number and the size of the metastasis 
nodules, indicating effects on seeding and persistent growth 
potential of Met­1 cells by 90% compared with heterozy­
gous littermates (Fig. 1 j). This is contributed by both the 
number and size of metastatic nodules that were significantly 
reduced in the homozygous mutant mice indicated by the me­
tastasis number index and average diameter, respectively (Fig. 1, 
k and l). Together, our data indicate that FLT1 had a limited 
role in the primary tumor invasion and intravasation but that 
both the metastasis rate­limiting steps of seeding and persistent 
growth at the distal organ of PyMT­induced tumors were de­
pendent on host FLT1 signaling.
Macrophage FLT1 signaling is critical  
for human breast cancer metastasis
Because the studies in the previous section indicate a role for 
host FLT1 in metastasis in two independent murine models 
of breast cancer, we wished to determine whether a similar 
mechanism is at play with human metastatic breast cancer cells. 
To this end, we used 4173 cells, the lung trophic derivative 
of the MDA­MB­231 human breast cancer cell line derived 
Figure 2. FLT1 tyrosine kinase domain is critical for 
human breast tumor cell metastasis. (a–d) Experimental 
metastasis of 4173 cells in Rag2/ littermate heterozygous 
or homozygous for Flt1tk targeted mutation with stereologi-
cal quantification. (e–h) Distal metastasis efficiency of 4173 
cells in bone marrow mosaic nude mice with littermate  
donor of Rag2/; Flt1tk/+ or Rag2/; Flt1tk/tk mice with ste-
reological quantification. Metastasis quantification was the 
same as in Fig. 1. Data show mean + SEM. n ≥ 5; *, P < 0.05; 
**, P < 0.01 by Student’s t test.
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CD163­labeled TAMs by immunofluorescent staining (Fig. 3 g). 
Using a tissue array that contains 50 cases of primary tumor 
and 55 metastases, FLT1 was shown to predominantly label 
macrophage­like stromal cells (CD68+) and endothelial cells 
(Fig. 3 h) and was rarely expressed by tumor cells (3 out of 
105 cases). Interestingly, FLT1+ macrophages were signifi­
cantly enriched in metastases compared with the matched 
primary tumors, data which suggest these cells may play a 
role in disease progression (Fig. 3 i). Together, our data indi­
cate the FLT1 signaling in MAMs may play an important role 
for human breast cancer metastasis.
FLT1 inhibition limits persistent growth of established tumor
In light of these results showing an effect of macrophage FLT1 
on metastasis growth, we postulated that targeting FLT1 might 
have therapeutic benefit by inhibiting metastasis. To test this 
hypothesis, we used a specific monoclonal FLT1­neutralizing 
antibody (MF1; Wu et al., 2006) to inhibit FLT1 signaling in 
experimental metastasis assay of Met­1 in syngeneic immune­
competent FVB mice in vivo (Fig. 4 a). Consistent with the 
(Fig. 2, g and h). Thus, we can conclude that human meta­
static cells are dependent on FLT1 signaling in bone marrow– 
derived cells for distal seeding and persistent growth.
To confirm the importance of FLT1 signaling in macro­
phages in another independent model, we crossed the 
macrophage­restricted Cre recombinase strain (Csf1r-iCre), 
where the Cre is expressed from the promoter of the Csf1r 
gene (Deng et al., 2010), with Flt1flox/flox mice to generate 
macrophage­restricted Flt1 gene–ablated mice (Stefater et al., 
2011). These mice were then bred with nude mice to generate 
immune­deficient mice that allow metastasis assays of 4173 
human breast cancer cells (Fig. 3 a). This Cre­mediated 
macrophage­specific Flt1 gene ablation resulted in an 90% 
reduction in the lung metastasis potential of inoculated 4173 
cells compared with Cre­negative littermates (Fig. 3, b–d). 
This inhibition is caused by a reduction in both the number 
and the size of metastasis nodules (Fig. 3, e and f).
To examine FLT1 expression in macrophages in patient 
samples of breast cancer, we preformed double immunofluor­
escent staining. FLT1 marks the majority (80%) of CD68­ and 
Figure 3. Macrophage-specific FLT1 
knockout inhibits human breast tumor 
cell distal metastasis. (a) Experimental 
metastasis assay of 4173 cells in nude mice 
with macrophage-specific Csf1r-iCre–induced 
Flt1 knockout and Cre littermate controls. 
(b and c) Representative H&E-stained lung 
section of lung metastasis in the indicated 
mice. (d–f) Stereological quantification of 
the distal metastasis efficiency of 4173 cells 
in macrophage-specific Flt1 knockout and 
littermate control. Metastasis quantification 
was the same as in Fig. 1. Data show mean + 
SEM. n ≥ 5; *, P < 0.05; **, P < 0.01 by Stu-
dent’s t test. (g) Representative micrographs 
showing colocalization of immunofluor-
escently stained FLT1 with macrophage 
markers using anti-CD68 (top) and CD163 
(bottom) antibodies in patient-derived  
breast tumor samples. (h) Representative 
FLT1 (top) and CD68 (bottom) immunohisto-
chemistry staining–labeled tumor stroma  
in breast cancer metastasis samples. Bars:  
(b and c) 1 mm; (g) 20 µm; (h) 100 µm.  
(i) Number of cases of FLT1-positive (+) and 
FLT1-negative (-) macrophage-like stroma  
in primary and metastatic breast cancer 
samples. P is calculated with Fisher’s  
exact test.
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monocytes. Quantification of absolute tumor cell number in 
lung indicated that the seeding step is estimated to finish at 
36 h, defined by the nadir of cell number, and is followed by 
exponential increase that defines persistent growth (Qian et al., 
2009). Using an ex vivo intact lung imaging technique, we 
found that FLT1 inhibition did not affect tumor cell extrava­
sation and MAM interaction (Fig. 4, e–g). This lack of require­
ment for extravasation is further confirmed using an in vitro 
extravasation assay (not depicted) that we established earlier 
(Qian et al., 2011). These data indicate that FLT1 signaling 
does not affect tumor cell extravasation during metastatic seed­
ing. In contrast, FLT1 inhibition by MF1 antibody in estab­
lished Met­1 lung metastasis 6 d after inoculation significantly 
genetic data descried above, FLT1 inhibition at the time of 
tumor cell inoculation significantly reduced metastasis effi­
ciency in vivo by targeting both the seeding and persistent 
growth steps compared with control­treated mice (Fig. 4, b–d, 
white and blue bars).
The use of FLT1 inhibitory antibody also enabled us to 
dissect distal metastatic events, i.e., extravasation, seeding, and 
persistent growth by giving the antibody at different time 
points according to tumor cell inoculation. In experimental 
metastasis assays with i.v. inoculated Met­1 cells, the majority 
of the tumor cells (75%) have completed extravasation 24 h 
after inoculation facilitated by direct contact with MAMs 
derived from CCL2/CCR2 signaling–recruited inflammatory 
Figure 4. FLT1 inhibition blocks breast 
cancer metastatic growth. (a) Schematic of 
experimental metastasis assay of Met-1 cells 
in syngeneic FVB mice with control antibody 
and FLT1 inhibitory antibody (MF1) treatment 
started at the indicated time related to tumor 
cell inoculation. (b–d) Stereological quantifi-
cation of the distal metastasis efficiency of 
Met-1 cells with control and MF1 treatment. 
Metastasis quantification was the same as  
in Fig. 1. Mean + SEM. n ≥ 5; *, P < 0.05;  
**, P < 0.01 by ANOVA plus Dunnett’s multiple 
comparison test. (e and f) Representative 
snapshots of 3D reconstructed confocal images 
of tumor cell (CFP, shown in blue) and macro-
phage (GFP, shown in green) 24 h after tumor 
cell tail vein injection in mice treated with 
control antibody (e) and MF1 (f). Bars, 200 µm. 
(g) Quantification of percentage of tumor 
cells that have extravasated 24 h after tail 
vein injection. Error bars indicate SEM. n = 3; 
not significant by Student’s t test. (h) Apopto-
sis index, defined by percentage of TUNEL-
positive tumor cells, in Met-1 cell lung 
metastasis with 2-d antibody treatment. Data 
show mean + SEM. n ≥ 3; **, P < 0.01 by 
ANOVA plus Dunnett’s multiple comparison 
test. (i) Proliferation index defined by percent-
age of Ki67-positive cells in total tumor cells. 
Data are shown as mean + SEM. n = 4; not 
significant by one-way ANOVA.
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signaling in MAMs is critical for the survival of seeded meta­
static tumors in our models.
To further test whether inhibition of FLT1 signaling may 
be effective in treating established metastatic disease, we per­
formed a spontaneous metastasis assay by orthotopic injection 
of a PyMT­induced mouse mammary tumor cell line, F246­
6, in syngeneic FVB mice, followed by tumor resection when 
they reached 1 cm in diameter 4 wk later (Fig. 5 a). FLT1 
inhibition after tumor resection significantly inhibited the 
metastasis burden and prolonged survival (Fig. 5, b and c). 
inhibited total metastasis burden and average diameter (Fig. 4, 
b and d, red bars), whereas, as expected, the number of meta­
static nodules remained unchanged (Fig. 4 c, red bar). This 
effect was mainly through an increase in apoptosis of meta­
static tumor cells (Fig. 4 h), without an effect on cell prolifer­
ation (Fig. 4 i). Treatment of Met­1 cells with MF1 in tissue 
culture had no effect on their growth, which is in line with 
their lack of expression of FLT1 (confirmed by both RT­
PCR and FACS; not depicted), thereby ruling out direct ef­
fects on tumor cells. Together these data indicated that FLT1 
Figure 5. FLT1 inhibition blocks breast cancer metastatic growth. (a) Spontaneous metastasis assay of F246-6 cells with antibody treatment after 
tumor resection. (b) Stereological quantification of metastasis index (the same as in Fig. 1). Data show mean + SEM. n ≥ 13; **, P < 0.01 by Student’s t 
test. (c) Survival curve of mice treated with control or MF1 antibodies. Death is defined when the mice became moribund. n ≥ 10; P = 0.0136 by log-rank test. 
(d) Representative immunohistograms of the indicated immune cell type showing fluorescent intensity of FLT1 (red) and isotype control (blue) staining.  
n = 3. (e) Mean fluorescent intensity of FLT1 expression in MAMs and lung-resident macrophages. n = 3; ***, P < 0.001 using two-way ANOVA followed  
by Šídák’s multiple comparisons test. (f) Percentage of MAMs (F4/80+CD11b+ and Gr1) in total hematopoietic cells in perfused lung 24 h after Ctrl Ab or 
MF1 administration. n ≥ 3; not significant by Student’s t test. (g) Percentage of major immune cell populations in total hematopoietic cells in perfused 
lungs 24 h after Ctrl Ab or MF1 administration. n = 3; not significant by Student’s t test. (e–g) Error bars indicate SEM. (h) Representative Western blot 
after IP of FLT1 and probing using the p-Tyr antibody in primary macrophages showing phospho-FLT1 (top) and total FLT1 (bottom) treated with the  
indicated growth factor or tumor cell condition medium. n = 3.
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analysis identified a set of 1,030 unique genes that were dif­
ferentially regulated by short­term (2 d) FLT1 inhibition, with 
p­value <0.05 by Student’s t test. Among these genes, 688 
genes were down­regulated and 342 genes were up­regulated 
by FLT1 inhibition. Hierarchical clustering with this gene set 
confirmed the distinct gene expression profile of MAMs with 
and without FLT1 inhibition (Fig. 6 b). Further bioinformatics 
analysis with Ingenuity Pathway Analysis (IPA) using infor­
mation contained in the Ingenuity Knowledge Base identified 
multiple gene function groups that were significantly en­
riched in the FLT1­regulated gene set by a right­tailed Fisher’s 
exact test and p­value <0.05 (Fig. 6 c). Interestingly, inflam­
matory response genes were the most significantly enriched 
function groups, with all 35 genes in this group differentially 
regulated by FLT1 inhibition. The majority of these genes en­
code secreted factors and cell surface molecules, indicating the 
potential role of FLT1 in regulation of the tumor­promoting 
function of MAMs by modulating the metastasis microenvi­
ronment (Fig. 6 d).
CSF1 acts downstream of FLT1 signaling  
to promote metastatic growth
Analysis of the IPA data showed that CSF1 has the most in­
teractions with other molecules in the inflammatory response 
function group (Fig. 6 d). Down­regulation of CSF1 expression 
by FLT1 inhibition led us to hypothesize that MAMs ex­
pressing CSF1 may be required for their function of promot­
ing metastatic growth. To test this hypothesis, we generated 
bone marrow mosaic mice using lethal irradiation followed 
by bone marrow transplantation using syngeneic FVB WT 
donor mice or those homozygous for the Csf1­null mutant 
gene Csf1op (Wiktor­Jedrzejczak et al., 1990) and preformed 
experimental metastasis assay in the mosaic mice using 
Met­1 cells (Fig. 7 a). In this assay, CSF1 deficiency in bone 
marrow–derived cells significantly inhibited tumor cell met­
astatic seeding and persistent growth in vivo (Fig. 7, b–e). This 
indicates that CSF1 expression by bone marrow–derived 
cells including macrophages is critical for tumor cell distal 
metastasis efficiency.
In light of these results, we postulated that if local CSF1 
expression by MAMs is critical for tumor cell metastatic effi­
ciency and functions downstream of FLT1 signaling, then a 
lung­specific induction of CSF1 expression should negate the 
effect of FLT1 inhibition by the neutralizing antibody, MF1. 
To test this, a transgenic mouse model allowing lung­specific 
CSF­1 expression was generated by crossing doxycycline­ 
inducible CSF1 expression mice (tetO-Csf1; Van Nguyen 
and Pollard, 2002) with mice expressing reverse tetracycline­
responsive trans­activator (rtTA) under the control of lung­
specific Ccsp gene promoter (Fig. 7 f; Tichelaar et al., 2000). 
Experimental metastasis assays were performed in these FVB 
mice using Met­1 cells treated with MF1 antibody after tumor 
cell metastatic seeding (4 d after inoculation). Lung­specific 
CSF1 expression in Ccsp-rtTA; tetO-Csf1 double transgenic 
mice induced by treatment with doxycycline significantly 
restored metastatic growth of Met­1 cells in the presence of 
Together, these data suggest that targeting FLT1 signaling may 
be effective in treating metastatic breast cancer.
FLT1 modulates inflammatory gene expression in MAMs
To examine cell surface FLT1 expression on bone marrow–
derived cells, we used flow cytometric analysis of the major 
leukocyte populations in immune­competent FVB mice bear­
ing experimentally induced Met­1 cell lung metastasis. MAMs, 
but not lung­resident macrophages, expressed a significant 
level of FLT1 (Fig. 5, d and e). Furthermore, Ly6c+ inflam­
matory monocytes, which are the precursors of MAMs (Qian 
et al., 2011), do not express FLT1, indicating that this recep­
tor is up­regulated upon differentiation after these precursors 
have been recruited to the metastatic site (Fig. 5 d). None of 
the other immune cell types, including Ly6c monocytes, 
granulocytes, nor T or B cells, express FLT1 (Fig. 5 d). There­
fore, our data suggest that specific FLT1 signaling in MAMs 
is critical for metastatic seeding and persistent growth of breast 
cancer cells in vivo.
FLT1 has been shown to mediate macrophage recruitment; 
however, FLT1 signaling in macrophages has been poorly 
explored. Intriguingly, direct measurement by FACS for 
CD11b+, F4/80+, and Gr1 MAMs show their recruitment 
to the lung after Met­1 experimental metastasis was not affected 
by FLT1 inhibition in vivo (Fig. 5 f). Thus, in the metastatic 
context, FLT1 does not act as a chemotactic receptor for 
MAMs, nor does its inhibition affect the recruitment of other 
major immune cell populations (Fig. 5 g). To determine 
whether the ligands of this receptor, VEGF and PlGF, activate 
tyrosine kinase activity in macrophages, we stimulated mouse 
BMMs that express FLT1 with these ligands and measured 
tyrosine phosphorylation by anti­FLT1 immunoprecipitation 
(IP) and Western blotting for phosphor­tyrosine. Both VEGF 
and PlGF stimulated FLT1 phosphorylation coupled with 
down­regulation of receptor expression (Fig. 5 h). This is 
consistent with the behavior of these FMS­like tyrosine kinase 
receptors that upon ligand binding and activation of the ki­
nase undergo receptor­mediated internalization and destruction 
(Roth and Stanley, 1992). The efficacy of the MF1 neutralizing 
antibody was confirmed by the complete inhibition of the 
kinase activity in its presence in BMMs (Fig. 5 h). We also 
measured the activity of Met­1–conditioned medium in this 
IP assay and found that it stimulated FLT1 receptor tyrosine 
phosphorylation that was also inhibited by MF1. This is con­
sistent with the expression of both VEGF and PlGF by Met­1 
cells (not depicted) and suggests that metastatic tumor cells may 
use these ligands to signal to MAMs in vivo.
These data indicated that FLT1 is not responsible for the 
recruitment of monocytes or MAMs to the metastatic site and 
led to the hypothesis that FLT1 modulates the expression of 
target genes in MAMs to promote metastasis. To identify FLT1­
regulated gene expression in MAMs in vivo, we treated mice 
bearing similar lung metastasis tumor burden of Met­1 cells 
with control or MF1 antibody. MAMs were FACS sorted based 
on their distinct cell surface markers and subjected to whole 
transcriptome microarray analysis (Fig. 6 a). Bioinformatic 
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may reflect the outgrowth of micrometastasis nodules that 
were not detectable in the control group (Fig. 7 h). In con­
trol mice with no FLT1 inhibition, lung­specific CSF1 over­
expression does not change tumor cell metastatic potential 
FLT1 inhibition compared with tetO-Csf1 single transgenic 
littermates treated in the same way (Fig. 7, g–i). Because in­
duction of CSF1 expression started after tumor cell seeding, the 
slight increase of metastasis nodules (although not significant) 
Figure 6. Transcriptome analysis of FLT1-regulated genes in MAMs. (a) Schematic illustration of microarray transcriptome analysis of FACS-sorted 
MAMs with control treatment (Ctrl Ab) and FLT1 inhibition (MF1). (b) Hierarchical clustering of FLT1-regulated transcripts distinguishes MAM samples with 
and without FLT1 inhibition. (c) Top 10 enriched function groups of differentially regulated genes in MAMs with FLT1 inhibition based on IPA. (d) Graphical 
representation of the molecular relationships of the inflammatory response function group genes enriched in FLT1-regulated transcripts. Molecules are repre-
sented as nodes, with the color indicating up (red)- or down-regulation (green) by FLT1 inhibition, and the shape represents the functional class of the gene 
product as indicated below. The biological relationship between two nodes is represented as a line (solid line: direct interaction, broken line: nondirect inter-
action). Asterisks indicate CSF1 as one of the gene products that has the most interaction with other gene products in the function group. All interactions are 
supported by references from the literature in the Ingenuity Knowledge Base.
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plus control and MF1 antibodies. FLT1 inhibition most no­
tably modulated the phosphorylation of p38 and FAK1 
3 h after treatment (Fig. 8 a, arrows). These results were 
confirmed by Western blots using anti­p38 and FAK1 anti­
bodies on cell lysates of BMMs from Flt1tk/tk mice com­
pared with heterozygous littermate control treated with 
Met­1 cell–conditioned medium (Fig. 8 b). Furthermore, 
treatment of BMMs with a FAK1­specific inhibitor (FAK 
inhibitor 14) significantly inhibited tumor cell–conditioned 
medium–induced CSF1 expression (Fig. 8 c). Together, these 
data indicate that FAK1 is the potential mechanistic link me­
diating FLT1 activation to downstream target gene expression.
compared with WT mice (not depicted). Together, these data 
indicated that local CSF1 expression in MAMs acts down­
stream of FLT1 to promote metastatic growth of breast tu­
mors in vivo.
FLT1 signaling regulates CSF1 expression through FAK1
To further investigate the signaling pathways downstream 
of FLT1 activation, we used a reverse phase protein array 
to determine a panel of 45 proteins and phosphor­proteins 
that covers the major signaling pathways and compared cell 
lysates of BMMs treated with Met­1 cell–conditioned medium 
Figure 7. FLT1-regulated CSF1 expression promotes breast tumor cell distal metastasis. (a) Schematic of experimental metastasis assay of 
Met-1 cells in mosaic mice of bone marrow CSF1-deficient and WT control. (b–e) Representative H&E-stained lung sections (b) and stereological 
quantification (c–e) of metastatic potential of Met-1 cells in bone marrow mosaic mice as shown in a. Csf1 WT bone marrow (+/+, white bars) and 
homozygous null mutant bone marrow (op/op, blue bars) are shown. Error bars indicate SEM. n = 7; **, P < 0.01; ***, P < 0.001 by Student’s t test. Bar, 
1 mm. (f) Schematic of metastasis assay of Met-1 cells with control antibody, FLT1 inhibition (MF1 treatment), and lung-specific doxycycline-inducible 
CSF1 expression. (g–i) Metastatic potential of Met-1 cells in mice as shown in f. Induced CSF1 expression with MF1 treatment (Ccsp-rTta +; tetO-Csf1, 
red bars) and littermate control (Ccsp-rTta ; tetO-Csf1, with control antibody [white bars] or with MF1 [blue bars]). Metastasis quantification was 
the same as in Fig. 1. Data show mean + SEM. n ≥ 6; ***, P < 0.001 by one-way ANOVA plus Tukey’s multiple comparison.
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signaling downstream of CCL2 (Kitamura et al., 2015). In the 
current study, we illustrated a new mechanism of metastasis­
promoting function of MAMs mediated by FLT1 receptor 
tyrosine kinase signaling, which may offer a new therapy tar­
get in treating metastatic disease of breast cancer.
Immunoprofiling of cell surface markers indicated that 
MAMs express high levels of FLT1. During angiogenesis, FLT1 
generally acts in a kinase­independent manner as a decoy re­
ceptor titrating the proangiogenic factor VEGF with a 10­fold 
higher affinity compared with VEGFR2 (Shibuya, 2006). 
In this role, FLT1 can be expressed by both endothelial cells 
(Hiratsuka et al., 1998) and macrophages (Stefater et al., 2011). 
There is also evidence that its tyrosine kinase signaling activ­
ity can recruit myeloid cells in developmental and tumor 
graft settings (Murakami et al., 2008). In this study, using a 
genetically modified mouse model, we showed that FLT1 
signaling is critical for spontaneous lung metastasis in immune­
competent mice. Furthermore, we demonstrated that macro­
phage FLT1 is essential for tumor cell seeding and persistent 
DISCUSSION
Compelling recent evidence indicated that TAMs are critical 
for metastatic progression in tumors (Mantovani and Sica, 
2010; Qian and Pollard, 2010). Studies, particularly in but 
not limited to, breast cancer (Lin et al., 2001; Coussens and 
Pollard, 2011) show these macrophages actions are at all stages 
in the metastatic cascade, including promotion of tumor cell 
migration and escape into the circulation (Wyckoff et al., 2007) 
and their subsequent extravasation, survival, and persistent 
growth at target organs (Qian et al., 2011). Our studies showed 
that macrophages associated with distal metastasis were de­
rived from a subset of circulating CCR2­expressing Ly6c+ 
monocytes upon CCL2 chemokine signaling and enhance 
tumor cell extravasation (Qian et al., 2011). Blockade of CCL2 
signaling inhibited MAM recruitment to metastatic sites, re­
duced metastasis, and prolonged survival of mice (Qian et al., 
2011). These MAMs also promote tumor cell survival through 
direct contact mediated by VCAM1 (Chen et al., 2011), and 
their retention in metastasis is mediated by a CCL3 autocrine 
Figure 8. FLT1-regulated CSF1 expres-
sion through p-FAK1. (a) Efficacy of FLT1 
blockade using MF1 antibody against a panel 
of 45 proteins and phosphor-proteins on a 
reverse protein array. Color bar shows rela-
tive expression value (global normalization, 
refer to Table S1 for epitope information). 
Phosphorylation of p38 and FAK1 show the 
most notable reduction upon FLT1 blockade 
using MF1 antibody. n = 2. (b) Western blot 
showing inhibition of phosphor-p38 and 
phosphor-FAK1 in BMMs from littermate 
mice heterozygous or homozygous for Flt1tk. 
Representative blot from two independent 
experiments. (c) FAK1 inhibitor blocks tumor 
cell–conditioned medium (CM)–induced 
mRNA Csf1 expression in BMMs. Data show 
mean + SEM. n = 3; *, P < 0.05 by ANOVA 
plus Dunnett’s multiple comparison test.
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mice (Bais et al., 2010). These data are consistent with those 
presented here for breast cancer models where we show in 
both spontaneous PyMT model and three different mouse 
and human experimental syngeneic or transplanted models 
that inhibition of FLT1 signaling either genetically or by an­
tibody inhibition markedly reduced pulmonary metastasis. 
Furthermore, in two independent syngenic models where we 
resected the primary tumor in the Flt1tk/tk bone marrow chi­
meric background or followed by MF1 treatment, we also 
observed inhibition of spontaneous metastasis. Importantly, 
our data in these models showed improved survival of the 
mice after FLT1 inhibition. Furthermore, we identified expres­
sion of FLT1 in macrophages in human breast cancer metas­
tasis that was significantly enriched at these sites compared 
with the primary tumor.
Interestingly, in our models of breast cancer metastasis, 
FLT1 is specifically expressed by MAMs but not by monocytic 
precursors or lung­resident macrophages, and FLT1 inhibition 
did not affect their recruitment. This is different from previ­
ous studies showing that FLT1 signaling mediated macrophage 
recruitment in response to pathogens and to gliomas in a xe­
nograft model (Murdoch et al., 2004; Murakami et al., 2008). 
In addition, CD45+c­Kit+ or Sca­1+ hematopoietic progeni­
tor cells were reported in models of melanoma and lung car­
cinoma (Lyden et al., 2001) but were very rare (<0.05% of 
total CD45+ cells) in metastasis­bearing lungs in the current 
study and did not change with FLT1 inhibition (unpublished 
data). Instead, in parallel to the inhibition of tumor cell meta­
static potential by FLT1 inhibitory antibody (MF1), FLT1 
phosphorylation induced in macrophages by its ligands and 
by tumor cell–conditioned medium was significantly blocked. 
This indicated that FLT1 inhibition by MF1 may alter the 
metastasis­promoting function of MAMs by deregulating 
downstream target genes. Indeed, using transcriptome analysis, 
we identified an FLT1­regulated gene expression signature 
dominated by inflammatory response genes in MAMs in vivo.
A set of inflammatory response–related genes are the most 
significantly enriched gene function group in FLT1­regulated 
genes. Among which, CSF1 is significantly down­regulated by 
FLT1 inhibition, suggesting a role for macrophage­synthesized 
CSF1 in metastasis promotion. CSF1 is a key cytokine for 
macrophage function in vivo being required for macrophage 
survival, proliferation, and differentiation, as well as being 
chemotactic to these cells (Chitu and Stanley, 2006). Our data 
showed that CSF1 expression in response to FLT1 signaling 
is critical for breast tumor metastatic seeding and growth. 
Because CSF1 receptor is restricted to monocytes/macrophages 
in adult mice (Byrne et al., 1981), these data indicate a novel 
CSF1­mediated autocrine signaling in MAMs downstream 
of FLT1. Importantly, using a lung­specific gain­of­function tet­
racycline­regulated system, we showed that lung­restricted 
CSF1 expression reverts the inhibitory effect of FLT1 inhibi­
tion by MF1 on metastatic growth. This provides genetic evi­
dence for CSF1 being epistatic to FLT1 in MAMs. CSF1 in 
turn has been shown to stimulate VEGF production in macro­
phages (Curry et al., 2008), suggesting a positive feedback 
growth during distal metastasis. These experiments included 
two independent models of lineage FLT1 ablation (Flt1flox/flox; 
Csf1r-iCre) and FLT1 kinase domain knockout (Flt1tk) in 
combination with bone marrow transplantation to confirm 
the requirement for FLT1 signaling for these protumoral func­
tions through its tyrosine kinase domain in macrophages. Our 
previous study (Qian et al., 2011) established an essential role 
for monocyte­derived VEGF through its ability to enhance 
vascular permeability. This VEGF production by monocytes 
and the expression of FLT1 on MAMs suggest, in addition to 
its effects on endothelial cells, an autocrine role that together 
with tumor cell–expressed VEGF may synergize in the meta­
static site to cause differentiation of the incoming monocytes 
to metastasis­promoting MAMs and their subsequent ability 
to promote metastatic growth.
Our data show that Flt1tk/tk mutation does not affect pri­
mary tumor growth in the PyMT model of breast cancer. 
However, inhibition of the FLT1 ligand PlGF has been re­
ported to inhibit tumor growth in the transplanted B6 mela­
noma and Panc02 models (Fischer et al., 2007). In contrast 
to this data, other studies using several different anti­PlGF 
antibodies or the Flt1tk/tk mutant failed to show inhibition of 
tumor growth in the same or in other transplantation models 
(Bais et al., 2010) or in GEM models of pancreatic cancer 
(Casanovas et al., 2005). These data suggest that the originally 
published observations with a single antibody might be the 
result off­target effects (Bais et al., 2010).
However, FLT1­expressing myeloid cells have been shown 
to play a role in metastasis. These FLT1­positive myeloid cells 
educated by the primary tumor have been shown to precon­
dition sites, known as premetastatic niches, distant to the tumor 
that enhance metastatic seeding in experimental metastasis 
models (Hiratsuka et al., 2002; Kaplan et al., 2005). These cells 
promote metastasis through MMP9 expression as well as en­
hancing fibronectin deposition that have the combined effect 
of promoting tumor cell adhesion and therefore metastatic 
seeding (Hiratsuka et al., 2002; Kaplan et al., 2005; Dawson 
et al., 2009a). Inhibition of FLT1 with MF1 antibody or in 
the Flt1tk/tk genetic background inhibited these actions and 
blocked metastasis (Kaplan et al., 2005). Furthermore, inhibi­
tion of clotting inhibited recruitment of the CD11b+ and 
F4/80+ cells and ablated the metastatic niche. Nevertheless, 
even in the presence of clotting, CD11b+ macrophage abla­
tion inhibited metastasis, indicating the central importance 
of the myeloid cell recruitment to metastatic enhancement 
(Gil­Bernabé et al., 2012). In direct contrast to these studies 
in a tumor resection model, Dawson et al. (2009b) were un­
able to inhibit metastasis in the LLC or B16 melanoma model 
with either MF1 antibody or in the Flt1tk/tk mutant mice. 
However, these studies relied on tumor resection by hind­limb 
amputation that might have perturbed the systemic environ­
ment or showed the continuing need for a primary tumor 
to maintain the effect. However, in experimental pulmonary 
metastasis assays using B16F10 cells that by definition lack an 
initiating tumor, a reduction of metastasis was observed by 
inhibition of FLT1 using either anti­PlGF antibodies or Flt1tk/tk 
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anti–human CD68 (Dako), and anti–human CD163 (AbD Serotec). Immuno­
histochemistry/immunofluorescence were performed using protocols rec­
ommended by the antibody providers. FLT1 staining was scored manually in 
a blinded fashion by an independent investigator, and no staining was scored 
as negative.
Cell culture and Western blot. E0771, mouse mammary adenocarci­
noma, cells were provided by E. Mihich (Roswell Park Cancer Institute, 
Buffalo, NY). Highly metastatic populations, E0771­LG, were obtained by 
in vivo selection of lung metastatic cells after i.v. injection in syngeneic 
C57BL/6 mice (Kitamura et al., 2015). F246­6 cells were derived from a 
late­stage mouse mammary tumor from MMTV­PyMT mice in syngeneic 
FVB background and showed high metastatic potential after orthotopic im­
plantation. All cells were cultured in DMEM supplemented with 10% FBS. 
Proliferation assays were performed in the presence of 30 µg/ml MF1 and 
control antibody, and cell numbers were counted using Guava (EMD Milli­
pore) at the indicated time point. BMMs were differentiated from bone 
marrow progenitor cells in the presence of 100 ng/ml CSF­1 for 7 d before 
being treated with FLT1 ligand or tumor cell condition medium (1:4 diluted 
in fresh medium) for 30 min. FLT1 was immunoprecipitated from total cell 
lysate using an anti­FLT1 antibody (Santa Cruz Biotechnology, Inc.), and 
tyrosine phosphorylation was detected using phospho­tyrosine antibody 
(Cell Signaling Technology). FAK1 and p38 antibodies for Western blotting 
were the same as those used in the protein array (Table S1). BMMs were 
treated with Met­1 cell–conditioned medium and FAK inhibitor 14 (10 µM 
final concentration; Sigma­Aldrich) before RNA was harvested for real­time 
PCR analysis to determine mRNA Csf1 expression. Primers used were the 
following: Csf1, 5­CTCATCTGGGATCCTCTCCA­3, 5­TGTCAA­
AAGGTGGCATTTCA­3; and Gapdh, 5­CCATCACCATCTTCCAG­
GAG­3, 5­TCTCCATGGTGGTGAAGACA­3.
Modified transwell invasion assay. 105 BMMs were plated in 24­well 
plates in complete M3 medium and incubated overnight. The BMMs were 
rinsed twice with PBS, and the medium was then changed to serum­free M3 
medium (containing 120 ng/ml CSF­1); control wells contained the same 
medium without macrophages. Transwell chambers coated with growth 
factor–reduced (GFR) Matrigel (8­µm pore; #354483; BD) were rehydrated 
for 2 h at 37°C. 3 × 104 tumor cells, which had been serum starved for 5 h, 
were plated in the upper chamber of the transwell. Tumor cells were allowed 
to invade for 24 h at 37°C. The transwell inserts were fixed with 4% parafor­
maldehyde for 15 min, and the cells on the upper surface were removed with 
a cotton swab. The inserts were stained with Hoechst and rinsed five times 
with PBS, and the membranes were mounted on glass coverslips using 
Mowiol. 10 random fields at 10× magnification per membrane were imaged, 
and the cells were counted using ImageJ (National Institutes of Health). Three 
independent experiments with duplicate transwells were performed.
Transendothelial cell migration assay. Transendothelial migration assay 
was performed as described previously (Qian et al., 2011). In brief, 104 en­
dothelium cells, 3B­11 (ATCC), were plated into the upper chamber of 
a GFR Matrigel invasion chamber (BD) in DMEM with 10% FBS. A mono­
layer was formed in 2 d and verified by microscopy. 104 BMMs or FACS­
sorted monocytes were loaded to the basolateral side of the insert and put 
into the plate well with DMEM with 10% FBS and 104 U/ml CSF­1 to 
allow attachment. 2 × 104 CellTracker CMRA (Invitrogen)–stained Met­1 
cells were loaded into the insert with DMEM in 0.5% FBS and 100 ng/ml 
CSF­1. FLT1 neutralizing antibody and control antibody were used at a 
concentration of 10 µg/ml to both sides of the insert. Plates were incubated 
under normal tissue culture conditions for 48 h before being fixed with 1% 
(wt/vol) paraformaldehyde. Quantification of transmigrated tumor cells was 
the same as described in the invasion assay in the previous section.
Experimental and spontaneous metastasis assay. 8­wk­old FVB females 
or 6­wk­old female nude mice were used for all experimental metastasis as­
says with 5 × 105 PyMT­induced tumor cells, Met­1, and 106 MDA231­derived 
loop. These findings provide a mechanistic basis for the clini­
cal observations that CSF1 expression is associated with poor 
prognosis and metastatic disease in breast cancer patients 
(Scholl et al., 1994, 1996; McDermott et al., 2002). Similar 
correlations were found for endometrial, ovarian, and pros­
tatic cancers, suggesting that similar FLT1­mediated mecha­
nisms may be at play in the metastasis of these cancers (Smith 
et al., 1995; Toy et al., 2001; Richardsen et al., 2008).
There is now substantial evidence that inflammation plays 
a critical role in promoting tumorigenesis and in the subse­
quent progression of tumors to malignancy (Mantovani et al., 
2008; Grivennikov et al., 2010; Coussens et al., 2013). In fact, 
every solid cancer appears to invoke an inflammatory response, 
and in contrast to original concepts, this reaction is largely 
tumor promoting. However, little is known about the mech­
anisms by which inflammatory responses influence metastasis. 
In this study, FLT1 blockade inhibits spontaneous metastasis 
after primary tumor removal and metastatic seeding and pro­
longed survival. Importantly, we define a novel coupling of 
FLT1 signaling in macrophages to the regulation of an inflam­
matory response at the site of metastatic seeding and growth. 
This response includes the important macrophage survival 
and differentiation factor CSF1 that, through an autocrine 
action in macrophages, promotes metastasis. These data pro­
vided a strong rationale for jointly targeting VEGF and CSF1R 
in patients to break this positively reinforcing autocrine loop 
and curb metastatic disease.
MATERIALS AND METHODS
Animals studies. All procedures involving mice were conducted in accor­
dance with National Institutes of Health regulations concerning the use and 
care of experimental animals. The study of mice was approved by the Albert 
Einstein College of Medicine Animal Use Committee. Transgenic mice ex­
pressing the PyMT oncogene under the control of MMTV LTR were pro­
vided by W.J. Muller (McMaster University, Hamilton, Ontario, Canada) and 
bred in house in FVB background. C57BL/6 Flt1tk/tk (Hiratsuka et al., 1998), 
C57BL/6 Flt1flox/flox (Ambati et al., 2006), and FVB Ccsp-rTta (Tichelaar et al., 
2000) mice were provided M. Shibuya (University of Tokyo, Tokyo, Japan), 
N. Ferrara (Genentech, South San Francisco, CA), and J. Wittset (University 
of Cincinnati, Cincinnati, OH), respectively. MMTV­PyMT; Flt1tk were 
generated in house by crossing two strains and maintained by intercross. 
Flt1tk were also crossed with Rag2/ (obtained from Charles River) to gen­
erate mice in immune­deficient background for metastasis assay using human 
breast cancer cells, 4173, or cells in FVB background, Met­1. The FVB 
Ccsp-rTta were crossed with tetO-Csf1 mice generated by our group previ­
ously (Lin et al., 2001). For generation of bone marrow mosaic mice, recipient 
mice at 3 wk of age were irradiated with gamma irradiation at 8 Gy to deplete 
endogenous hematopoietic cells and rested for 5 h before i.v. injection of 
total bone marrow cells from donor mice for reconstitution. These mice were 
then recovered for 4 wk before metastasis assays (see Experimental and spon­
taneous metastasis assay). FLT1­neutralizing antibody (MF1) was provided by 
ImClone Systems, a wholly owned subsidiary of Eli Lilly & Co. Antibodies 
were given at 40 mg/kg body weight via i.p. injection every 2 d at days indi­
cated in Fig. 4 a according to tumor cell inoculation. Control rat IgG (EMD 
Millipore) was administered at the same schedule. All in vivo experiments were 
at least two independent experiments with three to five mice for each group.
Human tissue array and immunohistochemistry. Tissue array of breast 
carcinoma and matched lymph node metastasis were obtained from US 
Biomax, Inc. Antibodies used were anti–human FLT1 (Novus Biologicals), 
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Reverse phase protein microarray. Quantification of the abundance of 
total protein and phosphorylated protein epitopes were calculated using the 
Zeptosens reverse phase protein microarray platform. After incubation of 
BMM cultures with Met­1–conditioned media with control antibody or 
MF1 incubation, cells were rinsed twice in ice­cold PBS and lysed in the 
CLB1 lysis buffer (Bayer Technology Services) at room temperature for 30 min. 
Lysates were collected and centrifuged in microcentrifuge at 14,000 rpm for 
5 min. Supernatants were collected and subjected to total protein determi­
nation, and lysates were normalized to 1 mg/ml concentration.
Before spotting cell lysates onto ZeptoMARK hydrophobic chips 
(Zeptosens), samples were diluted fivefold with CSBL1 spotting buffer 
(Zeptosens) to generate the primary spotting solution and then further di­
luted with 90% CSBL1/10% CLB1 to obtain four different protein con­
centrations corresponding to 100, 75, 50, and 25% of the primary spotting 
solution. For each of these four dilutions, individual spots were arrayed 
onto ZeptoMARK hydrophobic chips as single sample droplets of 400 pl, 
using a noncontact spotter equipped with piezo­electric microdispensers 
(Nano­Plotter NP2.1; GeSiM). After spotting, the chips were dried for 1 h 
at 37°C, blocked in an ultrasonic nebulizer (ZeptoFOG; Zeptosens) with 
CeLyA Blocking Buffer (BB1; Bayer Technology Services). Blocked chips 
were rinsed extensively with water (Milli­Q quality) and dried by centrifu­
gation at 200 g for 5 min.
Using the built­in microflow ZeptoCARRIER system (Zeptosens, Bayer 
Technology Services), the arrays were incubated with a panel of 45 primary 
antibodies (Table S1) overnight at room temperature. After rinsing the system 
with assay buffer, the secondary detection antibodies (anti–rabbit and isotype­
specific anti–mouse Alexa Fluor 647) were applied to appropriate subarrays 
for 2.5 h at room temperature in the dark. The excess secondary antibody 
was removed by washing with assay buffer, and fluorescence readout of the arrays 
was performed on the ZeptoREADER (Zeptosens) at an extinction wave­
length of 635 nm and an emission wavelength of 670 nm. The fluorescence 
signal was integrated over a period of 1–10 s, depending on the signal intensity. 
Array images were stored as 16­bit TIFF files and analyzed with the Zepto­
VIEW Pro software package (version 3.1; Zeptosens, Bayer Technology 
Services). Each sample 4­point concentration series is spotted onto the mi­
croarray chip between Alexa Fluor–conjugated BSA standards. Fluorescence 
intensity signals of each sample are calculated by optimized image analysis al­
gorithms and normalized to intensity values of BSA standards through a local 
2D quadratic function. A single relative fluorescence intensity (RFI) value 
was obtained by a weighted linear fit through sample dilutions representing 
the relative protein abundance across the sample series.
A panel of 45 protein analysts (see Table S1) were normalized by the fol­
lowing global normalization procedure using the entire antibody panel. (a) 
Determine median for each antibody across the sample set. (b) Divide each 
raw linear value by the median within each antibody to obtain the median­
centered ratio. (c) Calculate the median from median­centered ratio for each 
sample across the entire panel of antibodies. This median functions as a cor­
rection factor (COMPARE1) for protein loading adjustment. (d) Divide raw 
RFI data by the correction factor to obtain the normalized values. Global 
normalized data were used to generate a heat map. In addition, RFI ratios 
of phosphorylated p38 MAPK and phosphorylated FAK modifications to 
total protein were calculated by the ZeptoVIEW 3.1 software (Zeptosens) 
and plotted as bar graphs.
Statistical analysis. Unless specified otherwise, statistical analysis methods 
used were standard two­tailed Student’s t test for two datasets and ANOVA 
followed by multiple comparison tests for multiple datasets using Prism 
(GraphPad Software); p­values <0.05 (*), <0.01 (**), and <0.001 (***) were 
deemed as significant.
Online supplemental material. Table S1, included in a separate PDF 
file, lists antibodies used in the reverse phase protein array. Online supple­
mental material is available at http://www.jem.org/cgi/content/full/jem 
.20141555/DC1.
human tumor cells, respectively. If not specified, all animals were sacrificed 
2 wk after i.v. injection of PyMT cells or 4 wk for human tumor cells for op­
timal metastatic burden. 106 E0771­LG or F246­6 cells were injected into 
the fat pad of fourth mammary gland of C57BL/6 or FVB mice, respectively, 
at 7–8 wk of age to establish primary tumor. These tumors were then surgi­
cally removed when reaching 1 cm in diameter in 4 wk. Metastasis was 
allowed to develop for another 2 wk before harvesting lungs. For paraffin 
sections, before removal, lungs were injected with 1.2 ml of 10% (vol/vol) 
neutral buffered formalin by tracheal cannulation to fix the inner airspaces 
and inflate the lung lobes. Lungs were excised and fixed in formalin over­
night. A precise stereological method (Nielsen et al., 2001) with slight 
modification was used for lung metastasis quantification. In brief, paraffin­
embedded lungs were systematically sectioned through the entire lung with 
one 5­µm section taken in every 0.5­mm lung thickness. All the sections 
were stained with hematoxylin and eosin (H&E), and images were taken 
using an AxioScan.Z1 slide scanner (Carl Zeiss) and analyzed using Tissue 
Studio (Definiens; Figs. 2 and 5 h) or SV11 microscope (Carl Zeiss) with a 
Retiga 1300 digital camera (QImaging) and analyzed using ImageJ software 
(all other figures). As described earlier (Qian et al., 2009), three parameters 
(Mets index, Mets number index, and average diameter) were calculated to 
estimate total metastasis burden, seeding efficiency, and metastatic growth, 
respectively. Mets index is defined by the percentage of metastatic tumor 
volume in total lung volume. Mets number index is defined by number 
of tumor nodules per square millimeter of lung area, and average diameter 
of all tumor nodules is the average diameter in millimeters. Please note 
that the difference in volume is proportional to the cube of the difference 
in diameter.
FACS analysis. For FACS analysis, lungs were perfused briefly with cold 
PBS before harvest, minced on ice, and then digested with an enzyme mix 
of Liberase and Dispase (Invitrogen). Cells were blocked using anti–mouse 
CD16/CD32 antibody (eBioscience) for mouse cells or 10% goat serum for 
human cells before antibody staining. Antibodies used are the following: 
anti–mouse CD45 (30­F11), CD11b (M1/70), Gr1 (RB6­8C5), FLT1 
(141522; R&D Systems); CD4 (GK1.5), CD8a (53­6.7), CD19 (1D3), CD115 
(AFS98) Nk1.1 (PK136; eBioscience); and F4/80 (Cl:A3­1; AbD Serotec). 
FACS analysis was performed on an LSRII cytometer (BD), and data were 
analyzed using FlowJo software (Tree Star). Single cell gating using FSC/W 
and SSC/W and dead cell exclusion with DAPI staining were performed 
routinely during analysis.
FACS sorting of specific macrophage populations and gene expres-
sion array analysis. Fluorescently labeled antibodies and tissue preparation 
were the same as described for the FACS analysis in the previous section. 
Metastasis­recruited macrophages (F4/80+CD11b+Gr1) were sorted from 
lungs bearing experimental metastasis of Met­1 cells using a MoFlo (Dako). 
In each sample, purity was >98% by post­sort analysis. Total RNA was ex­
tracted from these sorted macrophages (RNeasy Mini kit; QIAGEN), and its 
quality was determined using Pico Chip with a 2100 Bioanalyzer (Agilent 
Technologies). High­quality RNA was amplified one round using a Mes­
sageAmp II aRNA kit (Ambion) and reverse­transcribed into double­strand 
cDNA. Samples where then submitted to NimbleGen for labeling and hy­
bridization on their mouse gene expression array (MM8). Two­tailed Stu­
dent’s t test was used to analyze the gene expression values with TM4 MeV 
microarray software suite (Saeed et al., 2003). Genes had 1.5­fold change and 
P < 0.05 in mean expression values in MAMs compared with FLT1 inhibi­
tion and control treated. Original data were deposited at Gene Expression 
Omnibus (accession no. GSE68843).
Bioinformatics. The Database for Annotation, Visualization and Integrated 
Discovery (DAVID), the NCBI Entrez Gene and Gene Reference into Func­
tion, the Mouse Genome Informatics, and extensive literature review were 
used for annotating regulated transcripts with precise gene ontology desig­
nation. Function gene group analyses were performed with IPA software 
(Ingenuity Systems).
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Supplemental Table 1 
Antibody Short Name in Fig 8 Supplier Order Number 
Akt Akt Cell Signaling Technologies 9272 
Akt P Thr308 P-Akt Cell Signaling Technologies 2965 
c-Jun N-term c-Jun Epitomics 1254-1 
c-Jun P Ser73 P-c-Jun Cell Signaling Technologies 9164 
ErbB-3/Her3/EGFR ErbB-3 Cell Signaling Technologies 4754 
ErbB-3/Her3/EGFR P Tyr1289 P-ErbB-3 Cell Signaling Technologies 4791 
FAK1   FAK1   Cell Signaling Technologies 3285 
FAK1 P Y397 P-FAK1 Cell Signaling Technologies 3283 
FLT3 P Tyr591 P Tyr591 P-FLT3  Cell Signaling Technologies 3461 
GSK-3-alpha/beta P Ser21/Ser9 P-GSK-3-alpha Cell Signaling Technologies 9331 
GSK-3-beta GSK-3-beta Cell Signaling Technologies 9315 
GSK-3-beta P Ser9 P-GSK-3-beta  Cell Signaling Technologies 9336 
MEK1/2 MEK1/2 Cell Signaling Technologies 9122 
MEK1/2 P Ser217/221 P-MEK1/2  Cell Signaling Technologies 9154 
mTOR mTOR Cell Signaling Technologies 2972 
mTOR P Ser2448 P-mTOR1 Cell Signaling Technologies 2971 
mTOR P Ser2481 P-mTOR2 Millipore (Upstate) 09-343SP 
p38 MAPK p38 MAPK Cell Signaling Technologies 9212 
p38 MAPK PThr180,Tyr182 P-p38 MAPK Cell Signaling Technologies 9211 
p44/42 MAPK (ERK1/2) p44/42 MAPK Cell Signaling Technologies 9102 
p44/42 MAPK (ERK1/2) P Thr202/Thr185,Tyr204/
Tyr187 P-p44/42 MAPK  Cell Signaling Technologies 4370 
p70 S6 Kinase p70 S6 Kinase Cell Signaling Technologies 9202 
p70 S6 Kinase P Thr389 P-p70 S6 Kinase1 Epitomics 1175-1 
p70 S6 Kinase P Thr421,Ser424 P-p70 S6 Kinase2 Cell Signaling Technologies 9204 
p90 S6 kinase (Rsk1-3) p90 S6 kinase  Santa Cruz sc-231 
p90 S6 kinase (Rsk1-3) P Thr359,Ser363 P-p90 S6 kinase  Cell Signaling Technologies 9344 
PI3 Kinase p110-alpha PI3K Cell Signaling Technologies 4249 
PKC (pan) P Ser660 (beta-2) P-PKC  Cell Signaling Technologies 9371 
PKC substrate P (R/K)X(S*)(Hyd)(R/k) PKC  Cell Signaling Technologies 2261 
PKC-zeta PKC-zeta Cell Signaling Technologies 9372 
PKC-zeta/lambda P Thr410/403 P-PKC-zeta/lambda  Cell Signaling Technologies 9378 
PLC-gamma1 PLC-gamma1 Cell Signaling Technologies 2822 
PLC-gamma1 P Tyr783 P-PLC-gamma1 Cell Signaling Technologies 2821 
Prohibitin Prohibitin Santa Cruz sc-28259 
PTEN PTEN Cell Signaling Technologies 9552 
PTEN P Ser380,Thr382,Thr383 P-PTEN Cell Signaling Technologies 9554 
Raf  P Ser259 P-Raf1 Cell Signaling Technologies 9421 
Raf  P Ser338 P-Raf2 Cell Signaling Technologies 9427 
Rsk2 Pser 227 P-Rsk2  Cell Signaling Technologies 3556 
S6 Ribosomal Protein S6 Ribosomal Protein Cell Signaling Technologies 2217 
S6 Ribosomal protein P Ser235,Ser236 P-S6 Ribosomal protein1 Cell Signaling Technologies 2211 
S6 Ribosomal protein p Ser240,Ser244 P-S6 Ribosomal protein2 Cell Signaling Technologies 2215 
SHP2 P Tyr542 P-SHP2  Cell Signaling Technologies 3751 
Src  Src  Cell Signaling Technologies 2109 
Src (family) P Tyr416 P-Src Cell Signaling Technologies 2101 
